News
YS
0.9779
+2.93%
0.0278
Weekly Report: what happened at YS last week (0506-0510)?
Weekly Report · 5d ago
YS Biopharma appoints Dave Chenn as interim CEO
Healthcare YS Biopharma appoints Dave Chenn as interim CEO. The company also appointed Hui Shao, the then-current CEO, as the Co-Chief Executive Officer and Chief Business Officer. YS biopharma will hold an Extraordinary General Meeting on May 21.
Seeking Alpha · 05/07 20:31
Weekly Report: what happened at YS last week (0429-0503)?
Weekly Report · 05/06 11:17
YS Biopharma gets additional 180 days extension from Nasdaq
YS Biopharma gets additional 180 days extension from Nasdaq to regain compliance with its listing rules. The company is currently not in compliance with Nasdaq's minimum bid price rule. YS biopharma received an extension of 180 calendar days from the Nasdaq for compliance.
Seeking Alpha · 04/29 12:26
Weekly Report: what happened at YS last week (0422-0426)?
Weekly Report · 04/29 11:24
Weekly Report: what happened at YS last week (0415-0419)?
Weekly Report · 04/22 11:12
YS Biopharma reports 9M results
Seeking Alpha · 04/19 21:35
YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024
YS Biopharma Co reported earnings per share of -12 cents for the third quarter of 2024. The company reported revenue of $23.82 million. This was 4.27% better than the analyst estimate of $22.84 million for the same period.
Investorplace · 04/19 15:52
YS Biopharma Co Ltd: Report of foreign issuer
Press release · 04/18 16:01
YS BIOPHARMA CO LTD - PREPARING TO INITIATE A PHASE I CLINICAL TRIAL FOR YS-HBV-002 IN PHILIPPINES, WHICH IS EXPECTED TO BEGIN IN JUNE 2024
Reuters · 04/18 12:00
Weekly Report: what happened at YS last week (0408-0412)?
Weekly Report · 04/15 11:04
Chinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor
YS Biopharma has announced interim results from the ongoing Phase 3 clinical trial of its next-generation PIKA Rabies Vaccine. The company says the vaccine can potentially meet the WHO's goal of a one-week rabies vaccine regimen. The FDA has granted the vaccine orphan drug designation for rabies.
Benzinga · 04/09 19:30
YS Biopharma Co Ltd: Report of foreign issuer
Press release · 04/09 14:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. MyMD Pharmaceuticals stock rose 33.85% and Addex Therapeutic stock rose 24.48% during the same session. Other gainers included Vincerx Pharma, Neogen and Tilray Brands.
Benzinga · 04/09 12:09
YS BIOPHARMA: PIKA RABIES VACCINE DEMONSTRATES NON-INFERIOR IMMUNOGENICITY TO GLOBALLY MARKETED COMPARATOR
Reuters · 04/09 12:00
Weekly Report: what happened at YS last week (0401-0405)?
Weekly Report · 04/08 11:09
YS BIOPHARMA ANNOUNCES FULL REPAYMENT OF US$40,000,000 LOAN FACILITY
Reuters · 04/03 12:00
Weekly Report: what happened at YS last week (0325-0329)?
Weekly Report · 04/01 11:07
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. Xilio Therapeutic (XLO) stock moved upwards by 223.94% during the session. Akanda (AKAN) shares increased by 27.1% and INVO Bioscience (INVO) stock increased by 16.36%. NuCana (NCNA) stock declined by 19.8% in the pre- market.
Benzinga · 03/28 12:06
Weekly Report: what happened at YS last week (0318-0322)?
Weekly Report · 03/25 11:10
More
Webull provides a variety of real-time YS stock news. You can receive the latest news about YS Biopharma Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About YS
YS Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.